Insider · CIK 0001899935
Bethany Sensenig
Files at KALV (KalVista Pharmaceuticals, Inc.), SUPN (SUPERNUS PHARMACEUTICALS, INC.), ACOG (Alpha Cognition Inc.). First filing Aug 18, 2025, latest Feb 23, 2026.
In brief
Bethany Sensenig files SEC Form 4 as director at SUPN (SUPERNUS PHARMACEUTICALS, INC.), and also at KALV (KalVista Pharmaceuticals, Inc.), ACOG (Alpha Cognition Inc.). Since Aug 18, 2025, Bethany Sensenig has reported 0 open-market buys worth $0 and 2 open-market sells worth $455k, the latest filed on Feb 23, 2026.
A track record needs three past buys with six months of prices behind them; Bethany Sensenig has 0, so none is measured yet.
The newest scored trade: sold $228k of SUPN on Feb 19, 2026, filed Feb 23, 2026, scored 21 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $228k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SUPN: SUPERNUS PHARMACEUTICALS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 21Weak | SUPERNUS PHARMACEUTICALS, INC. | $228k 4,475 shares | -100% | +70% from low-10% from high | |
| 43Moderate | SUPERNUS PHARMACEUTICALS, INC. | $227k 5,369 shares | -100% | +41% from low-1% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 19, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 4,475 0.01% of outstanding | $225k | Feb 19, 2026 | none |
| Aug 14, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 5,369 0.01% of outstanding | $229k | Aug 14, 2025 | none |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | KALV KalVista Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -45,000 | - | - | 0 | Jun 11, 2026 |
| Apr 16, 2026 | ACOG Alpha Cognition Inc. | AGrant or award Common Shares | +5,489 | $0.00 | $0 | 5,489 | Apr 17, 2026 |
| Apr 16, 2026 | ACOG Alpha Cognition Inc. | AGrant or award Common Share Optionsderivative | +6,991 | $0.00 | $0 | 6,991 | Apr 17, 2026 |
| Feb 19, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock10b5-1 | +4,475 | $0.00 | $0 | 4,475 | Feb 23, 2026 |
| Feb 19, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -1,217 | $50.31 | $61k | 3,258 | Feb 23, 2026 |
| Feb 19, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -3,258 | $51.27 | $167k | 0 | Feb 23, 2026 |
| Feb 19, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitderivative10b5-1 | -4,475 | $0.00 | $0 | 0 | Feb 23, 2026 |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitderivative | +2,989 | $0.00 | $0 | 2,989 | Feb 20, 2026 |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Director Stock Option (Right to Buy)derivative | +4,977 | $0.00 | $0 | 4,977 | Feb 20, 2026 |
| Oct 1, 2025 | KALV KalVista Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Oct 2, 2025 |
| Aug 14, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock10b5-1 | -5,369 | $42.25 | $227k | 0 | Aug 18, 2025 |
| Feb 22, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Director Stock Option (Right to Buy)derivative | +8,252 | $0.00 | $0 | 8,252 | Feb 26, 2024 |
| Feb 22, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitsderivative | +5,369 | $0.00 | $0 | 5,369 | Feb 26, 2024 |
Questions about Bethany Sensenig
Answered from the filings on this page, as of the latest one.
Is Bethany Sensenig buying or selling?
In the last 12 months Bethany Sensenig reported 0 open-market buys worth $0 and 1 open-market sell worth $228k on SEC Form 4; the latest was sold $228k of SUPN on Feb 19, 2026. Grants, option exercises and tax withholding are not counted.
How did Bethany Sensenig's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Bethany Sensenig has 0.
Where does Bethany Sensenig file Form 4?
Bethany Sensenig has filed Form 4 at SUPN (SUPERNUS PHARMACEUTICALS, INC.); KALV (KalVista Pharmaceuticals, Inc.); ACOG (Alpha Cognition Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.